肝细胞癌基因治疗： 现状及挑战

窦慧敏; 王万祥

doi:10.12449/JCH250931

肝细胞癌基因治疗：现状及挑战

DOI: 10.12449/JCH250931

窦慧敏¹,
王万祥^2, , ,

1.
内蒙古医科大学第一临床医学院，呼和浩特 010059
2.
内蒙古医科大学附属医院肝胆胰脾外科，呼和浩特 010059

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：窦慧敏负责搜集资料，撰写论文；王万祥负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王万祥， wwx6188@163.com （ORCID： 0009-0004-4147-0014）

计量
- 文章访问数: 141
- HTML全文浏览量: 44
- PDF下载量: 22
- 被引次数: 0
出版历程
- 收稿日期: 2025-02-10
- 录用日期: 2025-02-21
- 出版日期: 2025-09-25

Gene therapy for hepatocellular carcinoma： Current research status and challenges

Huimin DOU¹,
Wanxiang WANG^{2
, ,
,}

1.
The First Clinical Institute of Inner Mongolia Medical University，Hohhot 010059，China
2.
Department of Hepatobiliary，Pancreatic，and Spleen Surgery，The Affiliated Hospital of Inner Mongolia Medical University，Hohhot 010059，China

More Information

Corresponding author: WANG Wanxiang， wwx6188@163.com （ORCID： 0009-0004-4147-0014）

摘要

摘要: 肝细胞癌（HCC）作为全球常见的恶性肿瘤之一，多数病例确诊时已处于晚期阶段，因此预后较差且生存率低。传统治疗方法效果有限，而基因治疗作为一种新兴的治疗策略展现出巨大的潜力，同时面临着诸多挑战。本文主要介绍HCC基因治疗领域的最新进展，并分析该领域未来发展中亟待解决的关键问题。基因治疗凭借靶向性强、作用机制多样及个性化治疗的优点，已成为当前HCC的研究热点。虽然基因治疗在HCC治疗中仍处于探索阶段，但目前已取得一些初步研究成果。根据相关文献报道，基因治疗联合化学治疗、免疫治疗等其他治疗方法可提升疗效，并降低部分单药治疗的副作用。随着技术的不断进步，基因治疗有望为HCC患者带来新的希望。
- 癌，肝细胞 /
- 基因治疗 /
- 治疗学
Abstract: Hepatocellular carcinoma （HCC） is one of the most common malignant tumors worldwide， and most patients are in the advanced stage at the time of diagnosis， leading to a poor prognosis and a low survival rate. Traditional treatment methods often have limited efficacy， while gene therapy， as an emerging therapeutic strategy， has shown great potential with numerous challenges. This article mainly introduces the latest advances in the field of gene therapy for HCC and analyzes the key issues that need to be addressed in the future development of this field. Gene therapy has become a research hotspot in HCC due to its advantages of strong targeting， diverse mechanisms of action， and individualized treatment. Although gene therapy is still in the exploratory stage in the treatment of HCC， some preliminary research findings have been achieved. According to the reports in the literature， the combination of gene therapy with other treatment methods， such as chemotherapy and immunotherapy， can improve treatment outcomes and reduce the side effects of monotherapy. With the continuous advances in technology， gene therapy is expected to bring new hope to HCC patients.
- Carcinoma， Hepatocellular /
- Genetic Therapy /
- Therapeutics

HTML全文

参考文献(54)

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[2]	RUMGAY H, FERLAY J, de MARTEL C, et al. Global, regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022, 161: 108- 118. DOI: 10.1016/j.ejca.2021.11.023.
[3]	TOH MR, WONG EYT, WONG SH, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology, 2023, 164( 5): 766- 782. DOI: 10.1053/j.gastro.2023.01.033.
[4]	XU HC, WANG FL, XIE LH. Current status and perspectives in clinical treatment of intermediate and advanced primary hepatocellular carcinoma[J]. J Changchun Univ Chin Med, 2024, 40( 1): 103- 107. DOI: 10.13463/j.cnki.cczyy.2024.01.024. 许华晨, 王凤玲, 谢林虎. 中晚期原发性肝细胞癌的临床治疗现状与展望[J]. 长春中医药大学学报, 2024, 40( 1): 103- 107. DOI: 10.13463/j.cnki.cczyy.2024.01.024.
[5]	HU B, ZHONG LP, WENG YH, et al. Therapeutic siRNA: State of the art[J]. Signal Transduct Target Ther, 2020, 5( 1): 101. DOI: 10.1038/s41392-020-0207-x.
[6]	SETTEN RL, ROSSI JJ, HAN SP. The current state and future directions of RNAi-based therapeutics[J]. Nat Rev Drug Discov, 2019, 18( 6): 421- 446. DOI: 10.1038/s41573-019-0017-4.
[7]	ZOHEIR KMA, ABD-RABOU AA, DARWISH AM, et al. Inhibition of induced-hepatic cancer in vivo through IQGAP1-shRNA gene therapy and modulation of TRAIL-induced apoptosis pathway[J]. Front Oncol, 2022, 12: 998247. DOI: 10.3389/fonc.2022.998247.
[8]	KIM W, YE Z, SIMONENKO V, et al. Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors[J]. NAR Cancer, 2024, 6( 1): zcad059. DOI: 10.1093/narcan/zcad059.
[9]	LIU XX, ZHU L, MA JJ, et al. Target-specific delivery of siRNA into hepatoma cells’ cytoplasm by bifunctional carrier peptide[J]. Drug Deliv Transl Res, 2017, 7( 1): 147- 155. DOI: 10.1007/s13346-016-0348-1.
[10]	YOUNIS MA, KHALIL IA, HARASHIMA H. Gene therapy for hepatocellular carcinoma: Highlighting the journey from theory to clinical applications[J]. Adv Ther, 2020, 3( 11): 2000087. DOI: 10.1002/adtp.202000087.
[11]	ABDELLATIF AAH, YOUNIS MA, ALSOWINEA AF, et al. Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine[J]. Colloids Surf B Biointerfaces, 2023, 222: 113111. DOI: 10.1016/j.colsurfb.2022.113111.
[12]	LIU CH, CHERN GJ, HSU FF, et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice[J]. Hepatology, 2018, 67( 3): 899- 913. DOI: 10.1002/hep.29513.
[13]	DENG ZY, YANG H, TIAN YY, et al. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma[J]. Front Oncol, 2022, 12: 975408. DOI: 10.3389/fonc.2022.975408.
[14]	HERNÁNDEZ-ALCOCEBA R, SANGRO B, PRIETO J. Gene therapy of liver cancer[J]. Ann Hepatol, 2007, 6( 1): 5- 14. DOI: 10.1016/S1665-2681(19)31948-9.
[15]	The Nobel Prize in Chemistry 2020[EB/OL].[ 2025-01-19]. https://www.nobelprize.org/prizes/chemistry/2020/press-release/. https: //www.nobelprize.org/prizes/chemistry/2020/press-release/
[16]	WANG X, TANG Y, LU J, et al. Characterization of novel cytochrome P450 2E1 knockout rat model generated by CRISPR/Cas9[J]. Biochem Pharmacol, 2016, 105: 80- 90. DOI: 10.1016/j.bcp.2016.03.001.
[17]	NIU Y, LIN ZY, WAN A, et al. Loss-of-function genetic screening identifies aldolase a as an essential driver for liver cancer cell growth under hypoxia[J]. Hepatology, 2021, 74( 3): 1461- 1479. DOI: 10.1002/hep.31846.
[18]	WAN YF, GE K, ZHOU WJ, et al. C-X-C chemokine receptor 2(Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1(PD-L1)[J]. Biol Chem, 2021, 402( 6): 729- 737. DOI: 10.1515/hsz-2020-0328.
[19]	ZHANG ZF, GENG CL, SONG MF, et al. Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity[J]. J Hepatol, 2025: S0168- 8278( 25) 00064-9. DOI: 10.1016/j.jhep.2025.01.027.
[20]	SHI XY, ZHANG YY, WANG YC, et al. The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine[J]. Cell Death Differ, 2024, 31( 9): 1219- 1234. DOI: 10.1038/s41418-024-01323-4.
[21]	LI CJ, XIAO YX, ZHOU JL, et al. Knockout of onecut2 inhibits proliferation and promotes apoptosis of tumor cells through SKP2-mediated p53 acetylation in hepatocellular carcinoma[J]. Cell Mol Life Sci, 2024, 81( 1): 469. DOI: 10.1007/s00018-024-05518-3.
[22]	PALAZ F, OZSOZ M, ZARRINPAR A, et al. CRISPR in targeted therapy and adoptive T cell immunotherapy for hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2024, 11: 975- 995. DOI: 10.2147/JHC.S456683.
[23]	O’SHEA CC, JOHNSON L, BAGUS B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity[J]. Cancer Cell, 2004, 6( 6): 611- 623. DOI: 10.1016/j.ccr.2004.11.012.
[24]	MAKOWER D, ROZENBLIT A, KAUFMAN H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies[J]. Clin Cancer Res, 2003, 9( 2): 693- 702.
[25]	TAKAHASHI M, SATO T, SAGAWA T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor[J]. Mol Ther, 2002, 5( 5 Pt 1): 627- 634. DOI: 10.1006/mthe.2002.0589.
[26]	HAN SR, LEE CH, IM JY, et al. Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation[J]. Mol Ther Nucleic Acids, 2020, 23: 154- 168. DOI: 10.1016/j.omtn.2020.10.036.
[27]	YI L, NING Z, XU L, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: An open-label, single-arm, pilot study[J]. ESMO Open, 2024, 9( 2): 102239. DOI: 10.1016/j.esmoop.2024.102239.
[28]	YARCHOAN M, GANE EJ, MARRON TU, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1/2 trial[J]. Nat Med, 2024, 30( 4): 1044- 1053. DOI: 10.1038/s41591-024-02894-y.
[29]	YAO RH, XIE CY, XIA XJ. Recent progress in mRNA cancer vaccines[J]. Hum Vaccin Immunother, 2024, 20( 1): 2307187. DOI: 10.1080/21645515.2024.2307187.
[30]	WANG YH, ZHAO QF, ZHAO BY, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency[J]. Adv Sci(Weinh), 2022, 9( 11): e2105631. DOI: 10.1002/advs.202105631.
[31]	PENG S, CHEN SL, HU W, et al. Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma[J]. Cancer Immunol Res, 2022, 10( 6): 728- 744. DOI: 10.1158/2326-6066.CIR-21-0931.
[32]	ZHANG J, TANG DY, WANG CY, et al. Immunotherapy for hepatocellular carcinoma based on AFP antigen[J]. J East China Univ Sci Technol(Nat Sci Ed), 2025, 51( 2): 219- 227. DOI: 10.14135/j.cnki.1006-3080.20240601001. 张洁, 汤丁越, 王成烨, 等. 基于AFP靶点的肝细胞癌的免疫治疗研究[J]. 华东理工大学学报(自然科学版), 2025, 51( 2): 219- 227. DOI: 10.14135/j.cnki.1006-3080.20240601001.
[33]	ADU-BERCHIE K, BROCKMAN JM, LIU YT, et al. Adoptive T cell transfer and host antigen-presenting cell recruitment with cryogel scaffolds promotes long-term protection against solid tumors[J]. Nat Commun, 2023, 14( 1): 3546. DOI: 10.1038/s41467-023-39330-7.
[34]	SHI YP, SHI DH, CHI JC, et al. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: A proof-of-concept treatment strategy[J]. Cancer Commun(Lond), 2023, 43( 9): 1064- 1068. DOI: 10.1002/cac2.12472.
[35]	CAPPELL KM, KOCHENDERFER JN. Long-term outcomes following CAR T cell therapy: What we know so far[J]. Nat Rev Clin Oncol, 2023, 20( 6): 359- 371. DOI: 10.1038/s41571-023-00754-1.
[36]	DIMITRI A, HERBST F, FRAIETTA JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing[J]. Mol Cancer, 2022, 21( 1): 78. DOI: 10.1186/s12943-022-01559-z.
[37]	A phase I open label clinical trial evaluating the safety and antitumor activity of autologous T cells expressing enhanced TCRs spe⁃cific for alpha fetoprotein (AFPc332T) in HLA-A2 positive subjectswith advanced hepatocellular carcinoma (HCC) or other AFP ex⁃pressing tumor types[R/OL]. (2024-08-20) [2025-01-19]. https://clinicaltrials.gov/study/NCT03132792.
[38]	BAI HR, ZHU XY, GAO L, et al. ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFRα⁺ cancer-associated fibroblasts during hepatocarcinogenesis[J]. Cell Death Dis, 2025, 16( 1): 26. DOI: 10.1038/s41419-024-07270-9.
[39]	LI JL, HUANG LZ, HUANG XS, et al. Bioinformatics analysis on key genes related to prognosis,diagnosis,and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs[J]. J Jilin Univ(Med Edit), 2024, 50( 4): 1062- 1075. DOI: 10.13481/j.1671-587X.202404021. 黎金连, 黄岚珍, 黄希仕, 等. 肝细胞癌预后、诊断和免疫细胞浸润相关关键基因及其潜在治疗药物的生物信息学分析[J]. 吉林大学学报(医学版), 2024, 50( 4): 1062- 1075. DOI: 10.13481/j.1671-587X.202404021.
[40]	GUO HR, WANG ML, NI CY, et al. TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2025, 44( 1): 20. DOI: 10.1186/s13046-025-03287-w.
[41]	LYU YH, LI Q, XIE SN, et al. Synergistic ultrasound-activable artificial enzyme and precision gene therapy to suppress redox homeostasis and malignant phenotypes for controllably combating hepatocellular carcinoma[J]. J Am Chem Soc, 2025, 147( 3): 2350- 2368. DOI: 10.1021/jacs.4c10997.
[42]	ZHANG BC, LAI CM, LUO BY, et al. Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy[J]. Acta Pharm Sin B, 2024, 14( 7): 3205- 3217. DOI: 10.1016/j.apsb.2024.04.033.
[43]	XIE PY, YU MC, ZHANG B, et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma[J]. J Hepatol, 2024, 81( 1): 93- 107. DOI: 10.1016/j.jhep.2024.02.009.
[44]	FARINHA D, SARMENTO-RIBEIRO AB, FANECA H. Combination of gene therapy and chemotherapy in a new targeted hybrid nanosystem to hepatocellular carcinoma[J]. Int J Nanomedicine, 2024, 19: 12505- 12527. DOI: 10.2147/IJN.S474665.
[45]	RONG J, LIU TT, YIN XJ, et al. Co-delivery of camptothecin and miR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2024, 43( 1): 247. DOI: 10.1186/s13046-024-03167-9.
[46]	HADI M, QUTAIBA B ALLELA O, JABARI M, et al. Recent advances in various adeno-associated viruses(AAVs) as gene therapy agents in hepatocellular carcinoma[J]. Virol J, 2024, 21( 1): 17. DOI: 10.1186/s12985-024-02286-1.
[47]	DONG LQ, GAO Q. Multi-omics molecular subgrouping of hepatocellular carcinoma and its application in precision diagnosis and treatment[J] J Clin Hepatol, 2022, 38( 3): 510- 514. DOI: 10.3969/j.issn.1001-5256.2022.03.004. 董良庆, 高强. 肝细胞癌多组学分子分型及其在精准诊疗中的应用[J]. 临床肝胆病杂志, 2022, 38( 3): 510- 514. DOI: 10.3969/j.issn.1001-5256.2022.03.004.
[48]	KAZEMIAN P, YU SY, THOMSON SB, et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components[J]. Mol Pharm, 2022, 19( 6): 1669- 1686. DOI: 10.1021/acs.molpharmaceut.1c00916.
[49]	YU SJ, ZHAO RR, ZHANG BC, et al. Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma[J]. Asian J Pharm Sci, 2023, 18( 4): 100828. DOI: 10.1016/j.ajps.2023.100828.
[50]	LIN YQ, FENG KK, LU JY, et al. CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery[J]. J Control Release, 2023, 361: 727- 749. DOI: 10.1016/j.jconrel.2023.08.028.
[51]	WANG HX, LI MQ, LEE CM, et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: Challenges and opportunities for nonviral delivery[J]. Chem Rev, 2017, 117( 15): 9874- 9906. DOI: 10.1021/acs.chemrev.6b00799.
[52]	KALASEKAR SM, VANSANT-WEBB CH, EVASON KJ. Intratumor heterogeneity in hepatocellular carcinoma: Challenges and opportunities[J]. Cancers(Basel), 2021, 13( 21): 5524. DOI: 10.3390/cancers13-215524.
[53]	TORBENSON MS. Hepatocellular carcinoma: Making sense of morphological heterogeneity, growth patterns, and subtypes[J]. Hum Pathol, 2021, 112: 86- 101. DOI: 10.1016/j.humpath.2020.12.009.
[54]	YOUNIS MA, HARASHIMA H. Understanding gene involvement in hepatocellular carcinoma: Implications for gene therapy and personalized medicine[J]. Pharmgenomics Pers Med, 2024, 17: 193- 213. DOI: 10.2147/PGPM.S431346.